Nisa Investment Advisors LLC Boosts Position in Danaher Co. (NYSE:DHR)

Nisa Investment Advisors LLC raised its stake in Danaher Co. (NYSE:DHR) by 0.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 245,539 shares of the conglomerate’s stock after purchasing an additional 456 shares during the period. Nisa Investment Advisors LLC’s holdings in Danaher were worth $56,430,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Decker Retirement Planning Inc. acquired a new stake in Danaher during the 4th quarter worth $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher during the third quarter worth about $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the third quarter worth about $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at about $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher in the 3rd quarter valued at about $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. Scotiabank started coverage on Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Guggenheim began coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target for the company. KeyCorp raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Barclays reduced their target price on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Finally, Robert W. Baird lowered their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Stock Performance

Shares of DHR opened at $244.18 on Wednesday. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52-week low of $225.42 and a 52-week high of $281.70. The company has a 50-day simple moving average of $234.75 and a 200-day simple moving average of $253.50. The company has a market capitalization of $176.36 billion, a PE ratio of 46.60, a P/E/G ratio of 4.30 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period last year, the firm earned $2.02 EPS. Equities research analysts predict that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.